Natera, Inc. (NASDAQ:NTRA) Insider Sells $7,265,600.00 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 80,000 shares of Natera stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $90.82, for a total value of $7,265,600.00. Following the completion of the transaction, the insider now owns 117,560 shares of the company’s stock, valued at $10,676,799.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Natera Stock Down 2.3 %

NTRA opened at $85.28 on Friday. The business’s 50-day simple moving average is $86.05 and its 200-day simple moving average is $65.85. The company has a debt-to-equity ratio of 0.37, a quick ratio of 3.96 and a current ratio of 4.10. Natera, Inc. has a one year low of $36.90 and a one year high of $98.82. The stock has a market capitalization of $10.30 billion, a P/E ratio of -22.50 and a beta of 1.37.

Natera (NASDAQ:NTRA) last posted its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.09. The business had revenue of $311.11 million for the quarter, compared to analysts’ expectations of $300.38 million. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. Analysts anticipate that Natera, Inc. will post -2.35 EPS for the current year.

Hedge Funds Weigh In On Natera

Several institutional investors have recently added to or reduced their stakes in NTRA. RiverPark Advisors LLC acquired a new position in Natera in the 4th quarter valued at about $27,000. Principal Securities Inc. acquired a new position in Natera in the 4th quarter valued at about $32,000. Harvest Fund Management Co. Ltd acquired a new position in Natera in the 3rd quarter valued at about $44,000. Oliver Lagore Vanvalin Investment Group increased its position in Natera by 109.3% in the 4th quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 389 shares during the period. Finally, CWM LLC boosted its holdings in Natera by 224.4% in the 3rd quarter. CWM LLC now owns 1,317 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 911 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analysts Set New Price Targets

NTRA has been the subject of a number of recent research reports. Craig Hallum initiated coverage on Natera in a report on Monday, April 8th. They issued a “buy” rating and a $117.00 target price for the company. BTIG Research raised their price target on Natera from $75.00 to $85.00 and gave the company a “buy” rating in a research note on Friday, December 29th. Raymond James cut Natera from a “strong-buy” rating to an “outperform” rating and raised their price target for the company from $68.00 to $85.00 in a research note on Tuesday, February 20th. Stephens restated an “overweight” rating and issued a $78.00 price target on shares of Natera in a research note on Tuesday, January 30th. Finally, Canaccord Genuity Group raised their price target on Natera from $87.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, February 29th. One investment analyst has rated the stock with a sell rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and a consensus price target of $86.40.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.